Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
← catalyst calendarNCT06968975 · readout in 271 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-11 | actual | When the study began enrolling |
| Primary completion | 2027-05-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Polyneuropathy, Inflammatory Demyelinating, Chronic
Primary outcomes
what the primary-completion date above is the date OFI-RODS score at baseline
measured Baseline
Variations of I-RODS score over the study duration
measured From Baseline up to End of Study (2 years)
Variations of I-RODS score after treatment change
measured From baseline up to End of Study (approx. 2 years)
Annualized I-RODS response rate
measured Up to End of Study (approx. 2 years)
Annualized I-RODS relapse rate
measured Up to End of Study (approx. 2 years)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed